Cirius Therapeutics, formerly known as Octeta Therapeutics, is a clinical-stage pharmaceutical company focused on developing therapies to treat liver disease. The company's lead product is MSDC-0602K, a second-generation insulin sensitizer for the treatment of NASH. Cirius is actively enrolling patients in a Phase 2b clinical trial called the EMMINENCE trial, to evaluate MSDC-0602K in patients with NASH and liver fibrosis. For additional information on the EMMINENCE trial, please visit clinicatrials.gov using the identifier NCT02784444.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/14/17 | $40,000,000 | Series A |
Adams Street Partners Frazier Healthcare  Novo A/S Renaissance Venture Capital Fund | undisclosed |
